Boston, MA -- (SBWIRE) -- 04/10/2017 -- Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.

Get More Details on this Report and a Full Table of Contents at Global Dyslipidemia Drugs Market 2017-2021

Technavio's analysts forecast the global dyslipidemia drugs market to grow at a CAGR of 5.27% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global dyslipidemia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

-Americas
-APAC
-EMEA

Technavio's report, Global Dyslipidemia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-AstraZeneca
-Merck
-Pfizer
-Sanofi

Other prominent vendors

-Alnylam Pharmaceuticals
-Amarin Corporation
-Amgen
-Bristol-Myers Squibb
-Catabasis Pharmaceuticals
-Cerenis
-Cipla
-CJ HealthCare
-CKD Bio
-Daewoong Pharmaceutical
-Daiichi Sankyo
-Eli Lilly
-Esperion Therapeutics
-GlaxoSmithKline
-JW Pharmaceuticals
-Kadmon Pharmaceuticals
-Lupin Pharmaceuticals

Market driver

-Change in ATP guidelines for management of hypercholesterolemia.
-For a full, detailed list, view our report

Market challenge

-Drawbacks associated with current therapies.
-For a full, detailed list, view our report

Market trend

-Increased uptake of OTC drugs.
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2021 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: AstraZeneca, Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis, Cipla, CJ HealthCare, CKD Bio, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, JW Pharmaceuticals, Kadmon Pharmaceuticals, Lupin Pharmaceuticals

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

-PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025
-Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth
-Dyslipidemia Global Clinical Trials Review, H2, 2016
-Global Solid Tumors Drugs Market 2016-2020
-PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2025